BrainStorm Cell Therapeutics (BCLI): Pangali EV/EBITDA

Brainstorm Cell (BCLI) is implementing automated bioreactors to develop drugs for nerve cell degeneration, eliminating manual labor. The financial foundation relies on the results of clinical trials for ALS therapy, as the company lacks a steady stream of income. A powerful scientific staff is retained through a stock option system and the strategic hiring of top managers. This chart of stock quotes on GURU.Markets confirms these data, and the EV/EBITDA metric stands at .

The EV/EBITDA multiple compares the total enterprise value of a business, including net debt, with its operating profit before interest, taxes, depreciation, and amortization. A decline in this ratio typically signals that an asset is undervalued, whereas a sharp increase warns of the risk of overpayment. The price action of the EV/EBITDA multiple for Brainstorm Cell (BCLI) allows for an assessment of the capitalization of development costs for the NurOwn platform within the context of creating a unique cell therapy ecosystem.